{"doi":"10.1310/hct0805-328","title":"Effectiveness and Safety of Simplification Therapy with Once-Daily Tenofovir, Lamivudine, and Efavirenz in HIV-1–Infected Patients with Undetectable Plasma Viral Load on HAART","abstract":null,"journal":"HIV Clinical Trials","year":2007,"id":595903,"datarank":0.42498200160843247,"base_score":2.833213344056216,"endowment":2.833213344056216,"self_citation_contribution":0.42498200160843247,"citation_network_contribution":0.0,"self_endowment_contribution":0.42498200160843247,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":16,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1526111,"name":"Piedad Arazo","orcid":null,"position":1,"is_corresponding":false},{"id":1526113,"name":"Koldo Aguirrebengoa","orcid":null,"position":2,"is_corresponding":false},{"id":1526114,"name":"Daniel García-Palomo","orcid":null,"position":3,"is_corresponding":false},{"id":1526115,"name":"Ángel Chocarro","orcid":null,"position":4,"is_corresponding":false},{"id":1526116,"name":"Pablo Labarga","orcid":null,"position":5,"is_corresponding":false},{"id":1526117,"name":"María-José Muñoz-Sánchez","orcid":null,"position":6,"is_corresponding":false},{"id":1526118,"name":"Santiago Echevarría","orcid":null,"position":7,"is_corresponding":false},{"id":83682,"name":"José A. Oteo","orcid":"0000-0001-7080-6542","position":8,"is_corresponding":false},{"id":1526119,"name":"Javier Uriz","orcid":null,"position":9,"is_corresponding":false},{"id":1526120,"name":"Santiago Letona","orcid":null,"position":10,"is_corresponding":false},{"id":1372723,"name":"M. Carmen Fariñas","orcid":null,"position":11,"is_corresponding":false},{"id":1526121,"name":"Galo Peralta","orcid":null,"position":12,"is_corresponding":false},{"id":1526122,"name":"Javier Pinilla","orcid":null,"position":13,"is_corresponding":false},{"id":1526123,"name":"Pedro Ferrer","orcid":null,"position":14,"is_corresponding":false},{"id":1526124,"name":"Maria-Luisa Álvarez","orcid":null,"position":15,"is_corresponding":false},{"id":1526125,"name":"José A. Iribarren","orcid":null,"position":16,"is_corresponding":false},{"id":1526109,"name":"Julio Arrizabalaga","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Effectiveness and Safety of Simplification Therapy with Once-Daily Tenofovir, Lamivudine, and Efavirenz in HIV-1–Infected Patients with Undetectable Plasma Viral Load on HAART","abstract":"OBJECTIVE: To evaluate the effectiveness and tolerability of a simplification regimen with tenofovir DF (TDF), lamivudine (3TC), and efavirenz (EFV) in HAART-experienced HIV-1-infected subjects with sustained viral suppression. METHOD: Patients with HIV-1 RNA <200 copies/mL during the previous 6 months and who switched their current twice-daily or three-times-daily HAART to a simplified once-daily regimen of TDF (300 mg), 3TC (300 mg), and EFV (600 mg) were included. RESULTS: 154 patients (70% males, mean age 42 years) were included. Previous HAART included a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen in 55% of the patients and a thymidine analog in 87%. The percentage of patients with viral load <200 copies/mL in the intent-to-treat (ITT) data set was 83% at 6 months and 75% at 12 months (98% and 96%, respectively, in the on-treatment [OT] analysis). Five patients (3%) were identified as virologic failures according to the study protocol. The mean CD4 T-cell count increased significantly 12 months after simplification (from 570 to 632 cells/mm3; p < .01). At 12 months, mean triglyceride levels decreased from 233 to 170 mg/dL (p < .01) and mean cholesterol levels decreased from 205 to 189 mg/dL (p < .01). Thirty-three patients (21%) discontinued the study treatment prior to completing the 12-month follow-up. CONCLUSION: Simplification to a once-daily regimen containing TDF, 3TC, and EFV is virologically and immunologically effective, well-tolerated, and safe with benefits in the lipid profile in the majority of patients.","is_dataset_classified":null,"base_score":2.833213344056216,"endowment":2.833213344056216,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"17956834","pmcid":null,"openalex_id":"https://openalex.org/W2021582733","authors":[],"funders":[],"total_grants":0,"fwci":0.932,"citation_percentile":0.72317263,"influential_citations":0,"citation_trend":[{"year":2014,"count":2},{"year":2015,"count":1},{"year":2016,"count":1},{"year":2017,"count":1},{"year":2018,"count":1},{"year":2019,"count":1},{"year":2020,"count":1},{"year":2023,"count":1},{"year":2026,"count":1}],"oa_status":"bronze","license":null,"oa_locations":[{"url":"https://www.tandfonline.com/doi/pdf/10.1310/hct0805-328?needAccess=true&role=button","host_type":"journal"},{"url":"https://www.tandfonline.com/doi/pdf/10.1310/hct0805-328?needAccess=true&role=button","host_type":"publisher"},{"url":"http://www.tandfonline.com/doi/pdf/10.1310/hct0805-328","host_type":"publisher"},{"url":"https://doi.org/10.1310/hct0805-328","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/17956834","host_type":"repository"}],"fields_of_study":["HIV/AIDS drug development and treatment","HIV-related health complications and treatments","HIV Research and Treatment","Adenine","Adult","Alkynes","Anti-HIV Agents","Antiretroviral Therapy, Highly Active","Benzoxazines","CD4 Lymphocyte Count","Cholesterol","Cyclopropanes","Female","HIV Infections","Humans","Lamivudine","Male","Middle Aged","Organophosphonates","Patient Acceptance of Health Care","RNA, Viral","Tenofovir","Treatment Outcome","Treatment Refusal","Triglycerides","Viral Load"],"mesh_terms":["Tenofovir","Adenine","Adult","Alkynes","Cholesterol","Cyclopropanes","Female","Humans","Male","Middle Aged","Patient Acceptance of Health Care","RNA, Viral","Triglycerides","HIV Infections","Treatment Refusal","Treatment Outcome","CD4 Lymphocyte Count","Lamivudine","Anti-HIV Agents","Viral Load","Antiretroviral Therapy, Highly Active","Benzoxazines","Organophosphonates"],"keywords":["Efavirenz","Lamivudine","Regimen","Medicine","Tolerability","Viral load","Reverse-transcriptase inhibitor","Internal medicine","Gastroenterology","Human immunodeficiency virus (HIV)","Stavudine","Pharmacology","Antiretroviral therapy","Immunology","Adverse effect","Virus"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-27T18:03:06.898969Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}